第六届董事会第六次会议决议公告 证券代码：002198 证券简称：嘉应制药 公告编号：2023-026 第六届董事会第六次会议决议公告 本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 1、广东嘉应制药股份有限公司（以下简称"公司"） 第六届董事会第六次 会议通知已于 2023 年 8 月 15 日以专人送达、电子邮件和电话等方式送达全体董 事、监事及高级管理人员。2023 年 8 月 25 日，会议如期以现场结合视频和邮件 通讯方式举行。 2、会议应出席董事 9 人，实际出席董事 9 人，董事朱拉伊、郭华平、张富 明以通讯方式出席。 3、公司监事会成员和高级管理人员列席了会议。因个人工作安排原因，董 事长朱拉伊先生未能现场参会，会议由副董事长黄晓亮先生主持。 4、会议的召集、召开符合法律、法规及公司章程的规定，表决形成的决议 合法、有效。 二、董事会会议审议情况 广东嘉应制药股份有限公司 第六届董事会第六次会议决议公告 公司《2023 年半年度报告全文》（公告编号：2023-024）详见指定信息披 露媒体巨潮资讯网（www.cninf ...

证券代码：002198 证券简称：嘉应制药 广东嘉应制药股份有限公司 投资者关系活动记录表 编号：2023-015 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 及人员姓名 参加嘉应制药 2022 年度业绩网上说明会的投资者 时间 2023 年 5 月 10 日 15:00-17:00 地点 "全景•路演天下"（http://rs.p5w.net） "东方财富路演" （https://roadshow.eastmoney.com/） 上市公司 接待人员姓名 朱拉伊 董事长 黄晓亮 副董事长兼董秘 郭华平 独立董事 冯杰 财务总监 投资者关系活动 主要内容介绍 1、公司在以您为核心的董事会的努力下，取得了靓丽的业绩。 感谢您和董事会。希望您能继续带领公司走向更加辉煌的明天！ 答：尊敬的投资者，您好！非常感谢您的支持和对公司的美 好祝愿，新的一年公司将继往开来，在董事会及公司管理层的带 领下，以"以德正心、嘉惠于民"的理念，破难攻坚，踔厉奋发， 笃定前行，推动公司发展迈上新台阶，希望您能继续关注和支持 我们公司。 2、公司 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 128,497,088.51, representing a 6.56% increase compared to CNY 120,586,266.19 in the same period last year[5] - Net profit attributable to shareholders increased by 380.58% to CNY 12,185,969.05 from CNY 2,535,662.28 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 11,019,022.44, up 310.95% from CNY 2,681,378.06 in the previous year[5] - Basic and diluted earnings per share rose to CNY 0.0240, a 380.00% increase from CNY 0.0050 in the same quarter last year[5] - Total operating revenue for Q1 2023 was CNY 128,497,088.51, an increase of 6.9% compared to CNY 120,586,266.19 in Q1 2022[16] - Operating profit for Q1 2023 reached CNY 13,120,025.47, significantly up from CNY 3,888,881.56 in the same period last year, marking an increase of 237.5%[18] - Net profit attributable to the parent company was CNY 12,185,969.05, compared to CNY 2,535,662.28 in Q1 2022, representing a growth of 380.5%[19] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.0240, up from CNY 0.0050 in Q1 2022[19] Assets and Liabilities - Total assets decreased by 1.83% to CNY 831,190,971.73 from CNY 846,650,977.26 at the end of the previous year[5] - The company's total assets as of March 31, 2023, amount to CNY 831,190,971.73, down from CNY 846,650,977.26 at the beginning of the year[14] - The total current assets decreased to CNY 548,050,880.96 from CNY 557,432,509.74[13] - The total non-current assets decreased to CNY 283,140,090.77 from CNY 289,218,467.52[14] - The total current liabilities decreased to CNY 55,332,590.34 from CNY 82,947,126.75[14] - The total non-current liabilities remained relatively stable at CNY 35,254,397.84 compared to CNY 35,285,836.01 at the beginning of the year[14] - Total liabilities decreased to CNY 90,586,988.18 from CNY 118,232,962.76 year-over-year[18] Cash Flow - Cash flow from operating activities showed a net outflow of CNY 956,929.25, a decline of 187.25% compared to a net inflow of CNY 1,096,710.93 in the previous year[5] - Cash flow from operating activities showed a net outflow of CNY -956,929.25, a decrease from a net inflow of CNY 1,096,710.93 in the previous year[19] - The net cash flow from investment activities was -937,382.74 CNY, indicating a decrease compared to the previous quarter[20] - The total cash outflow from investment activities amounted to 51,324,780.00 CNY, with 50,000,000.00 CNY related to other investment activities[20] - The net cash flow from financing activities was -10,361,477.89 CNY, primarily due to debt repayment and dividend distributions[20] - The company reported a net decrease in cash and cash equivalents of 1,894,311.99 CNY for the quarter[20] - Cash and cash equivalents at the end of the reporting period are CNY 181,963,721.91, slightly down from CNY 183,858,033.90[13] Other Income and Expenses - The company received government subsidies amounting to CNY 1,378,263.01, contributing to a significant increase in other income by 8185.69%[8] - Other income increased to CNY 1,386,076.13 from CNY 16,728.56 in the previous year, indicating a significant rise in additional revenue sources[16] - The company reported a decrease in total operating costs to CNY 115,949,772.87 from CNY 116,699,221.13 in the previous year[16] - Research and development expenses were CNY 1,657,099.81, slightly down from CNY 1,737,267.90 in Q1 2022[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,688[10] - The top 10 shareholders hold a total of 11.27% (57,200,000 shares) by Dongfang Securities Co., Ltd.[10] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[5] Audit Status - The first quarter report was not audited, which may affect the reliability of the financial data presented[20]

Financial Performance - The company's operating revenue for 2022 was CNY 659,195,732.41, representing a 14.70% increase compared to CNY 574,713,387.08 in 2021[20]. - Net profit attributable to shareholders reached CNY 43,934,703.72, a significant increase of 2,874.05% from CNY 1,477,269.72 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 43,973,457.47, up 15,489.86% from CNY 282,064.41 in 2021[20]. - Basic earnings per share rose to CNY 0.0866, a 2,886.21% increase from CNY 0.0029 in 2021[20]. - Total assets at the end of 2022 were CNY 846,650,977.26, reflecting a 4.87% increase from CNY 807,337,692.89 at the end of 2021[20]. - The company's net assets attributable to shareholders increased by 6.42% to CNY 728,418,014.50 from CNY 684,483,310.78 in 2021[20]. - The net cash flow from operating activities decreased by 47.58% to CNY 27,154,401.73 from CNY 51,800,132.35 in the previous year[20]. - The company achieved total revenue of ¥659,195,732.41 in 2022, representing a year-on-year growth of 14.70%[77]. - Net profit for the year was ¥43,934,703.72, showing a significant increase of 2,874.05% compared to the previous year[77]. - The company generated a net cash flow from operating activities of ¥27,154,401.73[77]. Market and Industry Trends - The overall pharmaceutical industry in China saw a decline in revenue by 1.6% in 2022, while the traditional Chinese medicine sector experienced a revenue growth of 5.6%[36]. - The total healthcare expenditure in China reached CNY 75,593.6 billion in 2021, with a year-on-year growth of 9.82%[33]. - By the end of 2022, the number of people covered by basic medical insurance in China was approximately 1.35 billion, maintaining a coverage rate of over 95%[35]. - The pharmaceutical industry in China is characterized by strong demand due to factors such as economic growth, population aging, and expanded medical insurance coverage[43]. - The aging population in China is increasing, with 264 million people aged 60 and above, representing a 42.7% growth since 2010, creating a significant demand for healthcare services[60]. Research and Development - The company has focused on the research and development of traditional Chinese medicine products, aligning with national health policies promoting traditional medicine[30]. - The R&D expenses of A-share listed companies before 2017 reached CNY 6.151 billion in the first three quarters of 2022, with a year-on-year growth of 12.67%[41]. - The R&D expense ratio for these companies was 2.46% in 2022, indicating a continuous increase in R&D investment intensity[41]. - The company applied for and obtained 3 new utility model patents in 2022 to support its research and development efforts[84]. - The company completed major R&D projects, including the development of the "Jiegu" series products, aimed at enhancing market share and clinical precision[95]. Regulatory Environment - The management highlighted potential risks including industry policy changes and concentrated leading products[3]. - The company plans to enhance its quality control and management practices in response to regulatory changes aimed at ensuring drug safety and quality[58]. - The State Administration for Market Regulation has introduced a new classification for TCM registration, focusing on innovative and improved TCM products[54]. - The company is closely monitoring national policy directions and enhancing internal management to improve operational efficiency and resilience against policy risks[122]. Corporate Governance - The company has no controlling shareholder and operates independently in terms of business, personnel, assets, and finance[134]. - The board of directors consists of 7 members, including 3 independent directors, which complies with legal and regulatory requirements[135]. - The company has established a performance evaluation and incentive mechanism for its directors and senior management, ensuring transparency in appointments[137]. - The company respects and protects the rights of stakeholders, aiming for a balance of interests among all parties involved[139]. - The company has implemented various communication channels with shareholders, including phone calls and online meetings[133]. Environmental Responsibility - The company adheres to multiple environmental protection laws and industry standards, including the GB37823-2019 for air pollutants[182]. - The total emissions of nitrogen oxides from the company are within the limit of 150 mg/m³, with actual emissions recorded at 52-60 mg/m³[185]. - The company has a centralized wastewater discharge system with no reported exceedances in discharge standards[185]. - The company has increased its investment in environmental protection, focusing on wastewater and solid waste treatment, as well as maintenance and upgrades of pollution control facilities[194][195]. Employee Welfare and Management - The total number of employees at the end of the reporting period is 732, with 381 in the parent company and 351 in major subsidiaries[167]. - The company emphasizes employee training, focusing on enhancing overall capabilities and specific skills for middle and senior management[170]. - The company conducts regular health check-ups for workshop employees and provides necessary labor protection supplies and training to enhance safety awareness[199]. - The company has established a system for employee rights protection, including a workers' representative assembly to address issues related to wages, benefits, and labor safety[199].

关于举行 2022 年度网上业绩说明会并征集相关问题的公告 证券代码：002198 证券简称：嘉应制药 公告编号：2023-013 广东嘉应制药股份有限公司 关于举行 2022 年度网上业绩说明会并征集相关问题的公告 本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）《2022年年度报告》全文 及其摘要于2023年4月28日经公司第六届董事会第五次会议审议通过。本公司 《 2022 年 年 度 报 告 全 文 》 已 于 2023 年 4 月 29 日 刊 登 在 巨 潮 资 讯 网 站 （http://www.cninfo.com.cn）上，《2022年年度报告摘要》刊登在当日的《证 券 时 报 》 、 《 中 国 证 券 报 》 、 《 证 券 日 报 》 和 巨 潮 资 讯 网 站 （http://www.cninfo.com.cn）上，供全体股东和投资者查阅。 为使广大投资者进一步详细了解公司年报信息，公司将于2023年5月10日星 期三15:00-17:00，在全景网举行2022年度业绩网上说明会。 一、业 ...

Group 1: Natural Borneol Project - The purity of the company's natural borneol extraction ranges between 96% and 99%, with market prices for 96% purity around 3000 to 5000 RMB per kilogram [2][3] - The company has established pilot production lines for extraction and purification, which have been operational for over 2 years, with an expected annual capacity of 250 tons post-completion of facilities [3][4] - The domestic market demand for natural right-handed borneol is approximately 650 tons per year, while international demand is about 10,500 tons per year, indicating a significant market opportunity due to supply shortages [4][5] Group 2: Company Performance - The company's revenue for the first three quarters of the year reached 395 million RMB, with a net profit of 68 million RMB, reflecting a year-on-year growth of 325.29% [5][6] - The expected net profit for the entire year is projected to be between 68 million and 73 million RMB [5][6] - The subsidiary, Jinsan Pharmaceutical, is expected to achieve a net profit of 58.25 million RMB as per the profit compensation agreement [6][7] Group 3: Investment and Market Strategy - The company plans to focus future investments on the traditional Chinese medicine sector, emphasizing profitability in potential investments [7][8] - There is currently no intention to acquire hospitals or traditional Chinese medicine enterprises [7][8] - The company aims to enhance its market share and brand through increased advertising and sales team expansion, while also exploring external investments to improve overall profitability [8]

Group 1: Company Operations - The management structure of the company is stable, and the operational situation is normal [1] - Tiger Hui is not currently involved in the actual operations of the company, and there are no significant disagreements between the management and Tiger Hui [2] Group 2: Production and Capacity - The company’s subsidiary, Huqingyuan Bio, is expanding the cultivation of the Mei tree as planned, with natural borne ice currently in small-scale trial production [2] - The company is optimistic about the development prospects of the Mei tree industry, believing it will contribute to future performance [2] - The fundraising projects from the IPO, including the production of dual-purpose throat wind powder and solid essence ginseng pills, have been completed, with capacity utilization reaching approximately 100% [2] Group 3: Research and Development - The company’s new drugs, including diabetes and anti-tumor medications, are in different stages of development, with diabetes drugs in clinical stages and anti-tumor drugs in preclinical research [3] - The company will disclose any new developments in drug research in accordance with regulations [3] Group 4: Shareholder Actions - The company acknowledges that shareholders may reduce their holdings for personal financing or lifestyle improvements, complying with legal and regulatory requirements for information disclosure [3]

广东嘉应制药股份有限公司 2022 年第三季度报告 证券代码：002198 证券简称：嘉应制药 公告编号：2022-030 广东嘉应制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 167,762,966.29 | 11.47% | 414,613,931.27 | 2.94% | | 归属于上市公司股东 | 13,664,546.68 | 4,325.54% | 22,259,292.60 | 395.25% | | 的净利润（元） | | | | | | 归属于上市公司股东 的扣除非经常性损益 | 13,681,309.96 | 11,258.10% | 22,485,426.60 | 456.81% | | 的净利润（元） | | | | | | 经营活动产生的现金 | — | — | 598,47 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 246,850,964.98, a decrease of 2.15% compared to CNY 252,275,713.81 in the same period last year[21]. - The net profit attributable to shareholders increased by 105.33% to CNY 8,594,745.92, up from CNY 4,185,798.91 in the previous year[21]. - The net cash flow from operating activities surged by 305.52% to CNY 20,152,198.69, compared to CNY 4,969,459.88 in the same period last year[21]. - The basic earnings per share rose by 106.10% to CNY 0.0169, compared to CNY 0.0082 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 8,804,116.64, reflecting an increase of 111.59% from CNY 4,160,894.89 in the previous year[21]. - The company's gross profit margin for pharmaceutical products was 70.24%, down by 5.73% year-on-year, with a cost of sales increasing by 21.16% to CNY 73.45 million[50]. - The company reported a net loss of CNY 159,227,677.61 for the first half of 2022, an improvement from a loss of CNY 256,930,154.17 in the same period last year[152]. - The total profit for the first half of 2022 was CNY 11,444,075.52, an increase of 54.5% from CNY 7,435,843.44 in the first half of 2021[154]. Assets and Liabilities - Total assets decreased by 3.05% to CNY 782,741,827.83 from CNY 807,337,692.89 at the end of the previous year[21]. - Total liabilities decreased to CNY 89,663,771.13 from CNY 122,854,382.11, indicating a significant reduction in financial obligations[148]. - The company's equity attributable to shareholders increased to CNY 693,078,056.70 from CNY 684,483,310.78, reflecting a positive shift in retained earnings[148]. - The total assets at the end of the reporting period were 9.80 billion yuan, compared to 8.06 billion yuan in the previous year, indicating a growth of approximately 21.5%[167]. - The total liabilities at the end of the reporting period were 8.32 billion yuan, which is an increase from 7.50 billion yuan in the previous year[167]. Cash Flow - Cash received from operating activities rose by 46.06% to CNY 3,050,100 from CNY 2,087,400 year-on-year, attributed to increased recoveries of office petty cash and deposits[52]. - The net cash flow from operating activities for the first half of 2022 was ¥20,152,198.69, a significant increase from ¥4,969,459.88 in the same period of 2021, representing a growth of approximately 304%[160]. - The cash outflow for purchasing goods and services was ¥76,087,044.24, which is a substantial increase from ¥48,519,727.23 in the first half of 2021, indicating a rise of approximately 56.8%[160]. Business Operations - The company operates in the traditional Chinese medicine sector, with 70 product varieties across five dosage forms, focusing on orthopedics, throat, cold, and heat-clearing medicines[29]. - The company maintains a diverse product portfolio with 58 varieties across 5 dosage forms, including notable products like Shuangliao Houfeng San and Zhonggan Ling Pian[37]. - The company follows a sales model that emphasizes collaboration with medical institutions and compliance with local procurement pricing[35]. - The R&D focus includes projects like the Bone-setting series and various herbal formulations aimed at enhancing product offerings[36]. - The company has established a new platform for high-value-added products, achieving an annual production capacity of 960 tons for cosmetics and 480 tons for disinfectants[45]. Risks and Challenges - The company faces risks related to industry policy changes, product concentration, price declines, cost control, and new drug development[3]. - The company faces risks related to concentrated product lines, with key products directly impacting revenue and profitability, prompting a strategy to diversify product offerings[66]. - The company plans to enhance internal management and operational efficiency to mitigate risks from regulatory changes in the pharmaceutical industry[65]. - The company faces risks from price declines and cost control due to national policies that have led to a general downward trend in drug prices, impacting product costs and marketing expenses[67]. Environmental Compliance - The company is classified as a key pollutant discharge unit but has not exceeded emission standards for nitrogen oxides and sulfur dioxide[79]. - The company has established a pollution discharge permit valid from August 18, 2020, to August 17, 2023, with all major pollutants meeting discharge standards[84]. - The company has implemented emergency response plans for environmental incidents, with updates made as necessary[85][86]. - The company has implemented five key environmental protection measures, ensuring compliance with national and local pollution discharge standards[93]. Corporate Governance - The company held 1 annual general meeting, 5 board meetings, and 4 supervisory board meetings during the reporting period, ensuring compliance with governance structures[92]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[99]. - The company has engaged a third-party consulting firm to improve information disclosure practices and compliance with regulations[105]. Future Outlook - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[166]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings[166]. - The future outlook remains positive, with management guiding for continued revenue growth in the second half of 2022[176].

广东嘉应制药股份有限公司 2022 年第一季度报告全文 证券代码：002198 证券简称：嘉应制药 公告编号：2022-017 广东嘉应制药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 120,586,266.19 | 121,970,257.25 | -1.13% | | 归属于上市公司股东的净利润（元） | 2,535,662.28 | 7,764,3 ...